CYP2C9 polymorphisms are associated with phenytoin toxicity in South-Indian epileptic patients
| Autor: | Appa Rao Anumolu, Vengamma Bhuma, SV Naveen Prasad, Rakesh Reddy Reddigari, P Vgk Sarma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Phenytoin
medicine.medical_specialty Neurology PHENYTOIN TOXICITY business.industry lcsh:R south-india lcsh:Medicine medicine.disease Intensive care unit Gastroenterology law.invention polymorphism Epilepsy law cyp2c9 Internal medicine Toxicity phenytoin toxicity Medicine Outpatient clinic epilepsy business CYP2C9 medicine.drug |
| Zdroj: | Journal of Dr. NTR University of Health Sciences, Vol 9, Iss 2, Pp 92-97 (2020) |
| ISSN: | 2277-8632 |
| Popis: | Background and Aims: The contribution of CYP2C9 in phenytoin metabolism is generally modest, but it increases with increasing serum phenytoin concentration. In the current study, we sought to study the association of CYP2C9*2 and CYP2C9*3 polymorphism with clinical and biochemical phenytoin toxicity in epileptic patients presenting to a tertiary care hospital in South-India. Methods: In total, 50 patients on phenytoin therapy and clinically diagnosed with phenytoin toxicity in neurology outpatient department/casualty/intensive care unit and medicine wards were considered as cases. A total of 50 patients on phenytoin therapy without any evidence of toxicity were considered as controls. CYP2C9*2 (exon-3) and CYP2C9*3 (exon-7) gene polymorphisms were studied using the allele specific PCR method. Results: Out of 100 patients, CYP2C9*2 polymorphism was seen in 8 (8%) patients in which 6 (12%) were cases and 2 (4%) were controls. CYP2C9*3 polymorphism was seen in 23 (23%) patients out of which 17 (34%) were cases and 6 (12%) were controls. Mean serum phenytoin level in cases was 24.23 ± 1.3 μg/ml, whereas in controls, it was 17.10 ± 0.6 μg/ml and the difference was statistically significant with P value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|